Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 4, 2026

We're 6 Weeks Away From a Historic Change at the Federal Reserve -- and It May Be the Tipping Point for a Pricey Stock Market

View original at nasdaq.com
We're 6 Weeks Away From a Historic Change at the Federal Reserve -- and It May Be the Tipping Point for a Pricey Stock Market Key Points Jerome Powell's second term as Fed chair will conclude on May 15…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Warsh's potential appointment may represent the tipping point for a historically expensive stock market

    60% confidence
  • Kevin Warsh would prefer the central bank be a passive market participant, entailing selling off significant chunks of Treasury bonds and/or mortgage-backed securities

    60% confidence
  • His voting record strongly suggests he won't push for aggressive rate cuts

    60% confidence
  • Trump has vocally criticized Powell and the FOMC for not being more aggressive in lowering interest rates

    60% confidence
  • Trump prefers the federal funds rate be 1% or lower, compared with the current range of 3.50% to 3.75%

    60% confidence
  • Warsh remained persistently skeptical of inflation and often advocated that interest rates remain elevated even as unemployment rose during the financial crisis

    60% confidence
  • The stock market entered 2026 at its second-priciest valuation since January 1871, according to the S&P 500's Shiller Price-to-Earnings Ratio

    60% confidence
  • Lower interest rates would make it considerably easier for the U.S. to service its ever-growing national debt and would reduce borrowing costs for businesses

    60% confidence
  • Rate hikes now seem more likely than rate cuts in 2026

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com